Acute kidney injury (AKI) confers high morbidity and mortality. Even though patients survive, there is a substantial risk of progression to chronic kidney disease (CKD). Unfortunately, there is no effective therapy to retard this progression. ?Klotho (here referred as Klotho) was shown to effectively block this transition. But, whether Klotho?s renoprotection involves prevention of vascular rarefaction and whether the suppressive effect of Klotho on renal fibrosis is associated with the clearance of collagen are largely unknown. Abnormal autophagy may lead to renal tubular and vascular damage, and renal fibrosis. Vascular rarefaction and renal fibrosis contribute to CKD. Klotho deficiency is associated with impaired angiogenesis. But, it is unclear whether Klotho can rescue peritubular capillaries in AKI. Klotho was found to upregulate autophagy, improve revascularization, and promote collagen I degradation in vitro; but, how Klotho affects autophagy and if this effect modulates vascular rarefaction and fibrosis, and prevents progression to CKD needs to be defined. The central hypothesis is that Klotho prevents AKI transition to CKD by promoting autophagy, which in turn inhibits renal fibrosis and ameliorates vascular rarefaction. There are three specific aims to test this hypothesis.
Aim 1 investigates if Klotho increases autophagy flux in the kidney by (1) examining if Klotho upregulates renal autophagy flux in LC3 reporter mice; (2) defining the mechanisms of upregulation of autophagy by Klotho in vivo; (3) exploring how Klotho regulates autophagy flux in kidney cell line.
Aim 2 examines if Klotho inhibits renal fibrosis via upregulation of autophagy activity by (1) examining if Klotho upregulates autophagy and inhibits renal fibrosis post-IRI; (2) defining if autophagy levels influence renal fibrosis post-AKI using mice with low or high autophagy activity; (3) investigating how autophagy reduces collagen I or promotes the degradation of collagen I in GFP-collagen I transfected cells in vitro.
Aim 3 explores if Klotho ameliorates vascular rarefaction via upregulation of autophagy in endothelial cells post-AKI by (1) examining if Klotho restores peritubular capillaries with structural analysis (histology and high resolution ?CT), and measurement of renal blood perfusion and oxygenation (functional MRI, fMRI); (2) testing if Klotho blocks endothelial-mesenchymal transition in AKI mice with endothelial tracing markers; (3) confirming if Klotho protects endothelial damage and endothelial-mesenchymal transition in cultured endothelial cells via modulation of autophagy.
Aim 1 focuses on basic biology of Klotho effect on autophagy, which builds the basis for other two independent but scientifically interconnected Aims. This renewed proposal was built based on previous 5-year studies and will provide more evidence to support the concept that Klotho upregulates autophagy to inhibit fibrosis, ameliorates rarefaction after AKI and retards AKI-to-CKD progression. Developing new approaches to enhance renal vascular recovery and inhibit fibrosis is the translational objective of the proposal. Bringing Klotho to a therapeutic platform in human AKI is in the proximal future.

Public Health Relevance

Acute kidney injury (AKI) confers high morbidity and mortality; even though patients survive, there is a substantial risk of progression to chronic kidney disease (CKD). Unfortunately, there is no effective therapy to retard this progression. Klotho is a novel promising therapeutic strategy to prevent AKI transition to CKD by promoting autophagy, which in turn inhibits renal fibrosis and ameliorates vascular rarefaction.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK092461-09
Application #
9937698
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Sadusky, Anna Burkart
Project Start
2017-07-17
Project End
2022-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
9
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Fernández, Álvaro F; Sebti, Salwa; Wei, Yongjie et al. (2018) Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature 558:136-140
Song, Parkyong; Zechner, Christoph; Hernandez, Genaro et al. (2018) The Hormone FGF21 Stimulates Water Drinking in Response to Ketogenic Diet and Alcohol. Cell Metab 27:1338-1347.e4
Chen, Gaozhi; Liu, Yang; Goetz, Regina et al. (2018) ?-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553:461-466
Shi, Mingjun; Flores, Brianna; Li, Peng et al. (2018) Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a ""U-shaped"" relationship. Am J Physiol Renal Physiol 314:F501-F516
Gazdhar, Amiq; Ravikumar, Priya; Pastor, Johanne et al. (2018) Alpha-Klotho Enrichment in Induced Pluripotent Stem Cell Secretome Contributes to Antioxidative Protection in Acute Lung Injury. Stem Cells 36:616-625
Bian, Ao; Shi, Mingjun; Flores, Brianna et al. (2017) Downregulation of autophagy is associated with severe ischemia-reperfusion-induced acute kidney injury in overexpressing C-reactive protein mice. PLoS One 12:e0181848
Neyra, Javier A; Hu, Ming Chang (2017) Potential application of klotho in human chronic kidney disease. Bone 100:41-49
Yao, H; Ma, Y; Hong, Z et al. (2017) Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. Leukemia 31:2122-2131
Hu, Ming Chang; Shi, Mingjun; Gillings, Nancy et al. (2017) Recombinant ?-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int 91:1104-1114
Lu, Xiang; Hu, Ming Chang (2017) Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease. Kidney Dis (Basel) 3:15-23

Showing the most recent 10 out of 44 publications